NEW YORK CITY, NY / ACCESS Newswire / February 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

In high-income countries, more than 80% of children diagnosed with cancer will survive. Yet in some low- and middle-income ...

As an enterprise engaged in the development, manufacturing and commercialization of specialty plasma-derived therapeutics, ...

Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and ...

Israeli drug manufacturer Teva Pharmaceutical Industries has resumed the deliveries of the scarce epilepsy drug Finlepsin ...

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

DelveInsight's High Potency Active Pharmaceutical Ingredients Market Insights report provides the current and forecast market ...

The MSSG solidarity mechanism enables medicine sharing between EU states, with companies now required to report on drug ...